Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
复制标题
DOI：
10.1128/aac.02969-15
复制
发表时间：
2016-05-01
影响因子：
4.9
通讯作者：
Nguyen, M. Hong
中科院分区：
文献类型：
--
作者：
Buehrle, Deanna J.;Shields, Ryan K.;Nguyen, M. Hong
我们比较了38株美罗培南耐药铜绿假单胞菌分离株的头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、头孢他啶、头孢吡肟和哌拉西林-他唑巴坦MIC。没有分离株携带碳青霉烯酶; 74%为oprD突变体。头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对92%的分离株有活性，包括80%对所有三种β-内酰胺类耐药的分离株。43%的头孢他啶-阿维巴坦敏感分离株和6%的头孢洛扎-他唑巴坦敏感分离株在各自的折点处显示MIC。头孢洛扎-他唑巴坦和头孢他啶-阿维巴坦是美罗培南耐药铜绿假单胞菌感染的治疗选择，应谨慎使用以保持活性。
We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three beta-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.